Genes adaptability and NOL6 protein inhibition studies of fabricated flavan-3-ols lead skeleton intended to treat breast carcinoma

• Published in: International journal of biological macromolecules Vol. 258; no. Pt 1; p. 127661
• Main Authors: Mohammed Zaidh, S., Aher, Kiran Balasaheb, Bhavar, Girija Balasaheb, Irfan, N., Ahmed, Haja Nazeer, Ismail, Y.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-02-2024
• Subjects: Molecular docking; Molecular dynamic; Multi-omics analysis; NOL6 protein inhibitor; Trajectory analysis; NOL6 protein inhibitor; Trajectory analysis; Multi-omics analysis; Molecular docking; Molecular dynamic
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2023.127661

Breast cancer invasive 2.3 million women worldly and second prominent factor of cancer-related mortality. Finding a new site-specific and safe small molecule is a current need in this field. With the aid of deep learning Algorithms, we analyzed the published big database from cancer CBioportal to find the best target protein. Further, Multi-omics analysis such as enrichment analysis, scores of molecular, RNA biological function at a cellular level, and protein domain were obtained and matched to find the better hit molecules. The gene analysis output shows nucleolar protein 6 plays a significant responsibility in breast carcinoma and 354 natural and synthetic lead molecules are docked inside the active site. Docking result gave the output hit molecule falavan-3-ols with a binding score of −5.325 (Kcal/mol) and interaction analysis illustrates, 13 active amino acids favoring the binding interaction with functional groups of the hit molecule compared to the standard molecule Abemacilib (−2.857 (Kcal/mol)). Best docked complex of flavan-3-ols and NOL6 protein subjected to dynamic simulation 100 ns to study the stability. The results proved that π-π stacked, carbon‑hydrogen and electrostatic interactions are stable throughout the 100 ns simulation. The overall results conclude the hit molecule flavan-3-ol will be a safe and potent lead molecule to generate and treat breast carcinoma patients.